News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Advanced Cell Technology Announces Europe’s First Human Embryonic Stem Cell Transplant in Patient with Stargardt’s Disease


1/23/2012 6:41:37 AM

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced treatment of the first patient in its Phase 1/2 clinical trial for Stargardt’s macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The surgery was performed on Friday, Jan. 20, at the Moorfields Eye Hospital in London by a team of surgeons led by Professor James Bainbridge, consultant surgeon at Moorfields and Chair of Retinal Studies at University College London. The patient successfully underwent the procedure without any complications. ACT and Moorfields Eye Hospital received clearance in September from the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) to begin this trial in Europe.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES